EUK Fundamental Analysis - EUKEDOS SPA

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to EUK. EUK was compared to 32 industry peers in the Health Care Providers & Services industry. While EUK is still in line with the averages on profitability rating, there are concerns on its financial health. EUK is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

EUK had negative earnings in the past year.

In the past year EUK had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: EUK reported negative net income in multiple years.

Each year in the past 5 years EUK had a positive operating cash flow.

1.2 Ratios

EUK has a Return On Assets of -0.29%. This is amonst the worse of the industry: EUK underperforms 81.25% of its industry peers.

With a Return On Equity value of -1.76%, EUK is not doing good in the industry: 81.25% of the companies in the same industry are doing better.

With a Return On Invested Capital value of 2.53%, EUK is not doing good in the industry: 78.13% of the companies in the same industry are doing better.

Measured over the past 3 years, the Average Return On Invested Capital for EUK is below the industry average of 7.16%.

		Industry Rank	Sector Rank
ROA	-0.29%
ROE	-1.76%
ROIC	2.53%

ROA(3y)0.12%

ROA(5y)-0.11%

ROE(3y)0.54%

ROE(5y)-0.64%

ROIC(3y)2.58%

ROIC(5y)2.22%

1.3 Margins

EUK has a Operating Margin of 10.03%. This is amongst the best in the industry. EUK outperforms 90.63% of its industry peers.

In the last couple of years the Operating Margin of EUK has grown nicely.

The Gross Margin of EUK (94.58%) is better than 96.88% of its industry peers.

EUK's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	10.03%
PM (TTM)	N/A
GM	94.59%

OM growth 3Y-2.47%

OM growth 5Y3.88%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y0.24%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EUK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

EUK has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for EUK remains at a similar level compared to 5 years ago.

The debt/assets ratio for EUK has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.33, we must say that EUK is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of EUK (0.33) is worse than 78.13% of its industry peers.

A Debt/Equity ratio of 3.11 is on the high side and indicates that EUK has dependencies on debt financing.

EUK's Debt to Equity ratio of 3.11 is on the low side compared to the rest of the industry. EUK is outperformed by 71.88% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	3.11
Debt/FCF	N/A
Altman-Z	0.33

ROIC/WACC0.51

WACC5.01%

2.3 Liquidity

EUK has a Current Ratio of 0.38. This is a bad value and indicates that EUK is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Current ratio value of 0.38, EUK is not doing good in the industry: 84.38% of the companies in the same industry are doing better.

A Quick Ratio of 0.38 indicates that EUK may have some problems paying its short term obligations.

EUK's Quick ratio of 0.38 is on the low side compared to the rest of the industry. EUK is outperformed by 84.38% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.38
Quick Ratio	0.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EUK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -260.63%.

The Revenue has been growing slightly by 4.81% in the past year.

EUK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.94% yearly.

EPS 1Y (TTM)-260.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475.86%

Revenue 1Y (TTM)4.81%

Revenue growth 3Y6.09%

Revenue growth 5Y-0.94%

Sales Q2Q%3.39%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EUK. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EUK is on the same level as its industry peers.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	9.2

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EUK does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EUKEDOS SPA

BIT:EUK (10/10/2025, 7:00:00 PM)

0.72

-0.04 (-4.64%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners1.98%

Ins Owner ChangeN/A

Market Cap16.37M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.32
P/FCF	N/A
P/OCF	1.65
P/B	0.55
P/tB	1.7
EV/EBITDA	9.2

EPS(TTM)-0.05

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.58

FCFYN/A

OCF(TTM)0.44

OCFY60.69%

SpS2.22

BVpS1.31

TBVpS0.42

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-0.29%
ROE	-1.76%
ROCE	3.37%
ROIC	2.53%
ROICexc	2.6%
ROICexgc	3.01%
OM	10.03%
PM (TTM)	N/A
GM	94.59%
FCFM	N/A

ROA(3y)0.12%

ROA(5y)-0.11%

ROE(3y)0.54%

ROE(5y)-0.64%

ROIC(3y)2.58%

ROIC(5y)2.22%

ROICexc(3y)2.64%

ROICexc(5y)2.29%

ROICexgc(3y)3.08%

ROICexgc(5y)2.68%

ROCE(3y)3.43%

ROCE(5y)2.97%

ROICexcg growth 3Y-1.81%

ROICexcg growth 5Y0.32%

ROICexc growth 3Y-1.47%

ROICexc growth 5Y0.29%

OM growth 3Y-2.47%

OM growth 5Y3.88%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y0.24%

F-Score4

Asset Turnover0.28

Health

		Industry Rank	Sector Rank
Debt/Equity	3.11
Debt/FCF	N/A
Debt/EBITDA	7.67
Cap/Depr	327.21%
Cap/Sales	45.72%
Interest Coverage	250
Cash Conversion	82.01%
Profit Quality	N/A
Current Ratio	0.38
Quick Ratio	0.38
Altman-Z	0.33

F-Score4

WACC5.01%

ROIC/WACC0.51

Cap/Depr(3y)160.89%

Cap/Depr(5y)115.09%

Cap/Sales(3y)22.9%

Cap/Sales(5y)16.27%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-260.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475.86%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)4.81%

Revenue growth 3Y6.09%

Revenue growth 5Y-0.94%

Sales Q2Q%3.39%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-2.86%

EBIT growth 3Y3.47%

EBIT growth 5Y2.9%

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-466.09%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-1.41%

OCF growth 3Y20.95%

OCF growth 5Y10.45%

EUKEDOS SPA (EUK.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens